Permax was approved in 1988 for Eli Lilly and Company as an adjunctive therapy with levodopa in Parkinson's disease.
Permax是伊莱·利利公司于1988年获得批准的、作为辅助治疗药物与左旋多巴用于帕金森氏症的治疗。
Permax was approved in 1988 for Eli Lilly and Company as an adjunctive therapy with levodopa in Parkinson's disease.
Permax是伊莱·利利公司于1988年获得批准的、作为辅助治疗药物与左旋多巴用于帕金森氏症的治疗。
应用推荐